Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-863233 in Refractory Hematologic Malignancies
NCT00838890Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BMS-863233 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Tolerated Dose and Anti-tumor activity. Started Mar 2009; status: terminated.
02
Drugs
BMS-863233
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00838890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838890.